Jon A. Schwartz

Jon A. Schwartz

Auto-generated profile, based on publicly available information

Jon A. Schwartz

Clinical Research, Nanospectra Biosciences, Inc., Houston, Texas

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2008 in Optics Express
Verified
Journal Article
Open access
PDF file
JPJaesook Park
Jaesook Park
AEArnold Estrada
Arnold Estrada
KSKelly Sharp
Kelly Sharp
KSKrystina Sang
Krystina Sang
JSJon A. Schwartz
Jon A. Schwartz
JTJames Tunnell
James Tunnell
Gold nanoshells (dielectric silica core/gold shell) are a novel class of hybrid metal nanoparticles whose unique optical properties have spawned new applications including more sensitive molecular assays and cancer therapy. We report a new photo-physical property of nanoshells (NS) whereby these particles glow brightly when excited by near-infrared light. We characterized the luminescence brightness of NS, comparing to that of gold nanorods (NR) and fluorescent beads (FB). We find that NS are as bright as NR and 140 times brighter than FB. To demonstrate the potential application of this bright two-photon-induced photoluminescence (TPIP) signal for biological imaging, we imaged the 3D distribution of gold nanoshells targeted to murine tumors.

15 March 2011 in Lasers in Surgery and Medicine
Verified
Journal Article
Closed access
PDF file
JSJon A. Schwartz
Jon A. Schwartz
RPRoger E. Price
Roger E. Price
KGKelly L. Gill‐Sharp
Kelly L. Gill‐Sharp
KSKrystina L. Sang
Krystina L. Sang
JKJennifer Khorchani
Jennifer Khorchani
JPJ. Donald Payne
J. Donald Payne

28 July 2024 in Nanomaterials
Verified
Journal Article
Open access
PDF file
YKYara Kadria-Vili
Yara Kadria-Vili
JSJon A. Schwartz
Jon A. Schwartz
TPThomas J. Polascik
Thomas J. Polascik
GGGlenn P. Goodrich
Glenn P. Goodrich
DJDavid Jorden
David Jorden
ARArdeshir R Rastinehad
Ardeshir R Rastinehad
AuroLase® Therapy—a nanoparticle-enabled focal therapy—has the potential to safely and effectively treat localized prostate cancer (PCa), preserving baseline functionality. This article presents a detailed case of localized PCa treated with AuroLase, providing insight on expectations from the diagnosis of PCa to one year post-treatment. AuroLase Therapy is a two-day treatment consisting of a systemic infusion of gold nanoshells (~150-nm hydrodynamic diameter) on Day 1, and sub-ablative laser treatment on Day 2. Multiparametric MRI (mpMRI) was used for tumor visualization, treatment planning, and therapy response assessment. The PCa was targeted with a MR/Ultrasound-fusion (MR/US) transperineal approach. Successful treatment was confirmed at 6 and 12 months post-treatment by the absence of disease in MR/US targeted biopsies. On the mpMRI, confined void space was evident, an indication of necrotic tissues encompassing the treated lesion, which was completely resolved at 12 months, forming a band-like scar with no evidence of recurrent tumor. The patient’s urinary and sexual functions were unchanged. During the one-year follow-up, changes on the DCE sequence and in the Ktrans and ADC values assist in qualitatively and quantitatively evaluating tissue changes. The results highlight the potential of gold-nanoparticle-enabled sub-ablative laser treatment to target and control localized PCa, maintain quality of life, and preserve baseline functionality.

1 December 2024 in Journal of Urology
Verified
Journal Article
Open access
SCSteven E. Canfield
Steven E. Canfield
AGArvin K. George
Arvin K. George
JJJoshua Jue
Joshua Jue
SLSara Lewis
Sara Lewis
MDMatthew S. Davenport
Matthew S. Davenport
ARArdeshir R Rastinehad
Ardeshir R Rastinehad
Focal therapy aims to provide a durable oncological treatment option for men with prostate cancer (PCa), while preserving their quality of life. Most focal therapy modalities rely on the direct tissue effect, resulting in a possible nontargeted approach to ablation. Here, we report the results of the first human feasibility trial utilizing nanoparticle-directed focal photothermal ablation for PCa. A prospective open-label, single-arm multicenter study of men with localized PCa in the Gleason Grade Group (GGG) 1 to 3 was conducted. Men received a single infusion of gold nanoparticles (AuroShells), followed by MR/US fusion-guided laser excitation of the target tissue to induce photothermal ablation. MRI was used to assess the effectiveness of prostate tissue ablation at 48 to 96 hours, 3-months, and 12-months post-treatment. At 3 months, a targeted fusion biopsy of the lesion(s) was conducted. At 12 months a targeted fusion biopsy and standard templated biopsy were performed. Treatment success was determined based on a negative MR/US fusion biopsy outcome within the treated area. Forty-six men were enrolled in the study, and 44 men with 45 lesions completed nanoparticles infusion and laser treatment. The mean PSA level at baseline was 9.5 ng/mL, which decreased 5.9 ng/mL at 3-months and 4.7 ng/mL at 12-months (P < .0001). The oncologic success rates at 3- and 12-months resulted in 29 (66%) and 32 (73%) of 44 patients, respectively, being successfully treated confirmed with negative MR/US fusion biopsies within the ablation zone. Among GGG, maximum-lesion-diameter (MLD) on MRI, prostate volume, and PI-RADS scoring, the MLD was significantly associated with the odds of treatment failure at 12-months (P = .046). Nanoparticle-directed focal laser ablation of neoplastic prostate tissue resulted in 73% patients with successful treatment at 12-months post-treatment, confirmed by negative MR/US fusion biopsy of the treated lesion and a systematic biopsy.

10 February 2011
Verified
Conference Paper
Closed access
PDF file
JSJon A. Schwartz
Jon A. Schwartz
RPRoger E. Price
Roger E. Price
KGKelly L. Gill-Sharp
Kelly L. Gill-Sharp
KSKrystina L. Sang
Krystina L. Sang
JKJennifer D. Khorchani
Jennifer D. Khorchani
BGBradford S. Goodwin
Bradford S. Goodwin
This study adapted AuroLase® Therapy, previously reported for the treatment of brain tumors, to the treatment of prostate disease by 1) using normal canine prostate in vivo, directly injected with a solution of nanoparticles as a proxy for prostate tumor and, 2) developing an appropriate laser dosimetry for prostate which is which is subablative in native prostate while simultaneously producing photothermal coagulation in prostate tissue containing therapeutic nanoshells. Healthy, mixed-breed hound dogs were given surgical laparotomies during which nanoshells were injected directly into one or both prostate hemispheres. Laser energy was delivered percutaneously to the parenchyma of the prostate along 1-5 longitudinal tracts via a liquid-cooled optical fiber catheter terminated with a 1-cm isotropic diffuser after which the incision was closed and sutured using standard surgical techniques. The photothermal lesions were permitted to resolve for up to 8 days, after which each animal was euthanized, necropsied, and the prostate taken for histopathological analysis. We developed a laser dosimetry which is sub- to marginally ablative in native prostate and simultaneously ablative of prostate tissue containing nanoshells which would indicate a viable means of treating tumors of the prostate which are known from other studies to accumulate nanoshells. Secondly, we determined that multiple laser treatments of nanoshell-containing prostate tissue could be accomplished while sparing the urethra and prostate capsule thermal damage. Finally, we determined that the extent of damage zone radii correlate positively with nanoshell concentration, and negatively to the length of time between nanoshell injection and laser treatment.